Muehlenkreiskliniken AöR
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The department is testing innovative approaches for acute ischemic stroke, aiming to improve functional recovery and reduce disability.
- Acute ischemic stroke management
- Tenecteplase thrombolysis in patients on oral anticoagulants
- Sovateltide neuroprotective therapy
Muehlenkreiskliniken AöR contributes a dedicated team of investigators to advance stroke care in the region.
Digestive System Diseases
Research focuses on improving outcomes for patients with upper‑GI cancers, including gastroesophageal adenocarcinoma and advanced colorectal disease, by evaluating combination immunotherapy and peri‑operative regimens.
- Gastroesophageal adenocarcinoma
- Metastatic colorectal cancer
- Gastric cancer
- Adenocarcinoma of the esophagogastric junction
The site’s oncology unit is enrolling patients in several multicenter studies to refine therapeutic sequencing for digestive malignancies.
Hemic and Lymphatic Diseases
A broad portfolio addresses blood‑borne malignancies such as acute myeloid leukemia and various lymphomas, seeking to refine transplant strategies and targeted agents.
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Diffuse large B‑cell lymphoma
- Mantle cell lymphoma
- Multiple myeloma
- Primary myelofibrosis
- Polycythemia vera
- Essential thrombocythemia
Seventeen investigators collaborate on these studies, integrating novel agents with standard chemotherapy and transplant protocols.
Immune System Diseases
Trials evaluate novel biologics for chronic inflammatory skin conditions, including hidradenitis suppurativa, and explore therapies for systemic autoimmune lung involvement.
- Hidradenitis suppurativa
- Systemic sclerosis‑interstitial lung disease
- Connective tissue disease‑ILD
- Belimumab for CTD‑ILD
- Ruxolitinib for high‑risk polycythemia vera or essential thrombocythemia
The dermatology‑allergology department leverages its expertise in immune modulation to bring new options to patients with refractory disease.
Neoplasms
Oncology studies at the site test cutting‑edge immunotherapies for solid tumors such as advanced melanoma and non‑small cell lung cancer, while also addressing breast and skin cancers.
- Advanced melanoma
- Non‑small cell lung cancer (PD‑L1 positive)
- HR+/HER2‑ negative breast cancer
- Merkel cell carcinoma
- Basal cell carcinoma
Collaborative trials with international sponsors aim to expand the therapeutic arsenal for patients with high‑risk neoplasms.
Nervous System Diseases
Beyond stroke, the clinic investigates ways to lessen chemotherapy‑induced nerve damage, targeting chemotherapy‑induced polyneuropathy with protective agents.
- Chemotherapy‑induced polyneuropathy
- Acute cerebral ischemic stroke
- Neuroprotective agents for ischemic injury
These studies combine neurologic expertise with oncology to preserve quality of life during aggressive treatment.
Skin and Connective Tissue Diseases
Dermatology research includes evaluation of new systemic treatments for severe skin disorders like moderate‑to‑severe hidradenitis suppurativa and trials of checkpoint inhibitors in basal cell carcinoma.
- Moderate‑to‑severe hidradenitis suppurativa
- Basal cell carcinoma
- Cutaneous manifestations of systemic sclerosis
The clinic’s multidisciplinary approach integrates dermatologic assessment with immunologic monitoring to advance care for complex skin diseases.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 7 therapeutic areas and 15 of 114 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 112 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 25 by active trials.
- 1AstraZeneca AB3active
lock +24 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB4trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Muehlenkreiskliniken AöR
lock Showing 1 of 52 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of NAV-240 in Adults with Moderate-to-Severe Hidradenitis Suppurativa | Navigator Medicines Inc. | Phase II | Recruiting | Apr 2026 | — |
IMP list
lock Showing 1 of 114 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 10 | Unknown | 2022-05-11 | 2025-12-16 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.